Healthcare and Life Sciences Antitrust – The Year in Review and a Look Ahead to What You Need to Know for 2022


Please join our experienced healthcare and life science panelists as we recap dramatic developments in antitrust and healthcare policy over the Biden Administration’s first year and look ahead to what you need to know for 2022. 

  • Ongoing Overhaul of the Federal Agencies’ Approach to M&A and Merger Remedies
  • Increased Scrutiny of Provider Transactions
  • Developments around Private Equity in Healthcare and Life Sciences
  • Evolving Rules on Vertical Transactions and Arrangements
  • New Policies on Drug Pricing and Competition
  • Pending Legislation Targeting Antitrust in Healthcare

Our experienced panelists will share their insights and take your questions to prepare you for new antitrust challenges in 2022.

Jump to Page

By scrolling this page, clicking a link or continuing to browse our website, you consent to our use of cookies as described in our Cookie and Advertising Policy. If you do not wish to accept cookies from our website, or would like to stop cookies being stored on your device in the future, you can find out more and adjust your preferences here.